E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hematologic malignancies treated by reduced-intensity conditioning allogeneic transplants. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with cancer of the blood, bone marrow or lymph nodes treated with a low dose of chimiotherapy before bone marrow transplantation from a genetic similar donor. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10001756 |
E.1.2 | Term | Allogenic bone marrow transplantation therapy |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10018799 |
E.1.2 | Term | GVHD |
E.1.2 | System Organ Class | 100000004870 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The present project aims at comparing two postgrafting immunosuppressive regimens (Tac+MMF vs Tac+Sirolimus) after Flu-TBI or Flu-Bu-ATG. The hypothesis is that the Tac+Sirolimus regimen will be associated with better progression-free survival (due to a lower incidence of relapse/progression).To compare for 1-year progression-free survival between the 2 arms in the whole group of patients and separately in those conditioned with Flu-TBI or Flu-Bu-ATG.
Following the interim analysis of October 2014, the protocol has been amended to allow inclusion only after Flu-TBI conditioning since November the 3rd, 2014. |
|
E.2.2 | Secondary objectives of the trial |
Comparing
1.relapse rate, nonrelapse mortality, and OS in the 2 arms 1, 2 and 5 years after HSCT in all the patients and separately in those conditioned with Flu-TBI or Flu-Bu-ATG.
2.PFS in the 2 arms 2 and 5 years after HSCT, in all the patients and separately in those with Flu-TBI or Flu-Bu-ATG.
3.hematopoietic engraftment; evaluation 1-year of graft rejection in the 2 arms, in all the patients and separately in those with Flu-TBI or Flu-Bu-ATG.
4.6-mo of grades II-IV and III-IV acute GVHD in the 2 arms, in all the patients and separately in those with Flu-TBI or Flu-Bu-ATG.
5.1-yr of chronic GVHD in the 2 arms, in all the patients and separately in those with Flu-TBI or Flu-Bu-ATG.
6.quality and timing of immunologic reconstitution in the 2 arms, in all the patients and separately in those with Flu-TBI or Flu-Bu-ATG.
7.1-yr infections in the 2 arms, in all the patients and separately in those with Flu-TBI or Flu-Bu-ATG
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Hematological malignancies confirmed histologically and not rapidly progressing:
- AML in CR (defined as ≤ 5% marrow blasts and absence of blasts in the peripheral blood);
- MDS with ≤ 5% marrow blasts and absence of blasts in the peripheral blood;
- CML in CP;
- MPS not in blast crisis and not with extensive marrow fibrosis,
- ALL in CR;
- Multiple myeloma not rapidly progressing;
- CLL;
- Non-Hodgkin’s lymphoma (aggressive NHL should have chemosensitive disease);
- Hodgkin’s disease with chemosensitive disease.
Clinical situations:
•Theoretical indication for a standard allo-transplant, but not feasible because:
- Age > 50 yrs;
- Unacceptable end organ performance;
- At the physician’s decision;
- Patient’s refusal.
•Indication for a standard auto-transplant:
-perform mini-allotransplantation 2-6 months after standard autotransplant.
•Other inclusion criteria
-Male or female; fertile patients must use a reliable contraception method;
-Age ≤75 yrs (children of any age are allowed in the protocol);
-Informed consent given by patient or his/her guardian if of minor age.
|
|
E.4 | Principal exclusion criteria |
•Any condition not fulfilling inclusion criteria;
•HIV positive;
•Non-hematological malignancy(ies) (except non-melanoma skin cancer) < 3 years before nonmyeloablative HCT;
•Life expectancy severely limited by disease other than malignancy;
•Administration of cytotoxic agent(s) for “cytoreduction” within three weeks prior to initiating the nonmyeloablative transplant conditioning (Exceptions are hydroxyurea and imatinib mesylate);
•CNS involvement with disease refractory to intrathecal chemotherapy.
•Terminal organ failure, except for renal failure (dialysis acceptable)
-a.Cardiac: Symptomatic coronary artery disease or other cardiac failure requiring therapy; ejection fraction <35%; uncontrolled arrhythmia, uncontrolled hypertension;
-b.Pulmonary: DLCO < 35% and/or receiving supplementary continuous oxygen;
-c.Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin >3 mg/dL, and symptomatic biliary disease;
•Uncontrolled infection;
•Karnofsky Performance Score <70%;
•Patient is a fertile man or woman who is unwilling to use contraceptive techniques during and for 12 months following treatment;
•Patient is a female who is pregnant or breastfeeding;
•Any condition precluding the use of sirolimus or MMF.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Comparing the 1-year progression-free survival between the Tracolimus plus Mycophenolate Mofetil arm and the Tracolimus plus Sirolimus arm in the whole group of patients and separately in those conditioned with Flu-TBI or Flu-Bu-ATG before grafting. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
100 and 180 days post-engraftment.
The evaluation will continue the 2, 3, 4 and 5 year after post-engraftment. |
|
E.5.2 | Secondary end point(s) |
All the following comparisons will be done in the 2 arms, in the whole group of patients and separately in those conditioned with Flu-TBI or Flu-Bu-ATG:
1-Comparing relapse rate, nonrelapse mortality, and overall survival 1, 2 and 5 years after HSCT.
2-Comparing progression-free survival 2 and 5 years after HSCT.
3-Comparing hematopoietic (whole blood and T cell chimerism) engraftment and to evaluate the 1-year incidence of graft rejection.
4-Comparing the 6-mo incidence of grades II-IV and III-IV acute GVHD.
5-Comparing the 1-yr incidence of chronic GVHD..
6-Comparing the quality and timing of immunologic reconstitution.
7- Comparing the 1-yr incidences of bacterial, fungal and viral infections.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Evaluation of engraftment:
a) peripheral blood :
-Days 28, 42, 60, 100, 180 and 365 post-transplant : whole blood and CD3+ cells.
b) whole bone marrow :
-Days 42, 100, 180 and 365 post-transplant.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 12 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 12 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Five years after the last patient will be included in the trial and be transplanted |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 10 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 10 |